WO2021035854A1 - Vlbwi营养管理用特配液及其制备方法与应用 - Google Patents
Vlbwi营养管理用特配液及其制备方法与应用 Download PDFInfo
- Publication number
- WO2021035854A1 WO2021035854A1 PCT/CN2019/107976 CN2019107976W WO2021035854A1 WO 2021035854 A1 WO2021035854 A1 WO 2021035854A1 CN 2019107976 W CN2019107976 W CN 2019107976W WO 2021035854 A1 WO2021035854 A1 WO 2021035854A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- injection
- vlbwi
- nutrition
- groups
- birth
- Prior art date
Links
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 103
- 230000035764 nutrition Effects 0.000 title claims abstract description 97
- 238000002360 preparation method Methods 0.000 title claims description 27
- 229940088594 vitamin Drugs 0.000 claims abstract description 51
- 229930003231 vitamin Natural products 0.000 claims abstract description 51
- 235000013343 vitamin Nutrition 0.000 claims abstract description 51
- 239000011782 vitamin Substances 0.000 claims abstract description 51
- 239000000243 solution Substances 0.000 claims abstract description 44
- 239000002960 lipid emulsion Substances 0.000 claims abstract description 35
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 27
- 150000001413 amino acids Chemical class 0.000 claims abstract description 27
- 239000003792 electrolyte Substances 0.000 claims abstract description 24
- 239000008103 glucose Substances 0.000 claims abstract description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 229940090044 injection Drugs 0.000 claims description 64
- 239000007924 injection Substances 0.000 claims description 64
- 238000002347 injection Methods 0.000 claims description 64
- 235000015097 nutrients Nutrition 0.000 claims description 38
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 27
- 229940024606 amino acid Drugs 0.000 claims description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 229940093181 glucose injection Drugs 0.000 claims description 16
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 8
- -1 compound amino acid Chemical class 0.000 claims description 7
- 239000001103 potassium chloride Substances 0.000 claims description 7
- 235000011164 potassium chloride Nutrition 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 206010038933 Retinopathy of prematurity Diseases 0.000 abstract description 20
- 208000018773 low birth weight Diseases 0.000 abstract description 14
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 abstract description 13
- 231100000533 low birth weight Toxicity 0.000 abstract description 12
- 208000013016 Hypoglycemia Diseases 0.000 abstract description 11
- 208000033147 Parenteral nutrition-associated cholestasis Diseases 0.000 abstract description 11
- 206010040047 Sepsis Diseases 0.000 abstract description 11
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 11
- 208000004995 necrotizing enterocolitis Diseases 0.000 abstract description 11
- 208000030963 borderline personality disease Diseases 0.000 abstract 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 abstract 1
- 238000004904 shortening Methods 0.000 abstract 1
- 230000002028 premature Effects 0.000 description 43
- 238000001990 intravenous administration Methods 0.000 description 34
- 230000012010 growth Effects 0.000 description 26
- 235000016236 parenteral nutrition Nutrition 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 22
- 238000007726 management method Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 230000004584 weight gain Effects 0.000 description 18
- 235000019786 weight gain Nutrition 0.000 description 18
- 238000011161 development Methods 0.000 description 17
- 230000018109 developmental process Effects 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 16
- 238000011160 research Methods 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 230000036737 immune function Effects 0.000 description 15
- 206010051606 Necrotising colitis Diseases 0.000 description 10
- 208000012347 Parenteral nutrition associated liver disease Diseases 0.000 description 10
- 230000003908 liver function Effects 0.000 description 10
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 10
- 108010071690 Prealbumin Proteins 0.000 description 9
- 102000007584 Prealbumin Human genes 0.000 description 9
- 235000019577 caloric intake Nutrition 0.000 description 9
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 8
- 238000008789 Direct Bilirubin Methods 0.000 description 8
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 7
- 108010082126 Alanine transaminase Proteins 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 7
- 206010008635 Cholestasis Diseases 0.000 description 7
- 108010044091 Globulins Proteins 0.000 description 7
- 102000006395 Globulins Human genes 0.000 description 7
- 208000005107 Premature Birth Diseases 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 230000007870 cholestasis Effects 0.000 description 7
- 231100000359 cholestasis Toxicity 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000035935 pregnancy Effects 0.000 description 7
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 6
- 206010035664 Pneumonia Diseases 0.000 description 6
- 206010036590 Premature baby Diseases 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- WGXUDTHMEITUBO-YFKPBYRVSA-N glutaurine Chemical compound OC(=O)[C@@H](N)CCC(=O)NCCS(O)(=O)=O WGXUDTHMEITUBO-YFKPBYRVSA-N 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 206010041092 Small for dates baby Diseases 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 235000003715 nutritional status Nutrition 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 208000029028 brain injury Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 208000009206 Abruptio Placentae Diseases 0.000 description 3
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 208000036216 Placenta Previa Diseases 0.000 description 3
- 206010036603 Premature rupture of membranes Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 210000004381 amniotic fluid Anatomy 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000018823 dietary intake Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940037395 electrolytes Drugs 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 208000004104 gestational diabetes Diseases 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 235000006286 nutrient intake Nutrition 0.000 description 3
- 208000033300 perinatal asphyxia Diseases 0.000 description 3
- 201000008532 placental abruption Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 2
- 206010028923 Neonatal asphyxia Diseases 0.000 description 2
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 2
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010040049 Sepsis neonatal Diseases 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 208000028831 congenital heart disease Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 231100000001 growth retardation Toxicity 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 208000036796 hyperbilirubinemia Diseases 0.000 description 2
- 230000009602 intrauterine growth Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000003821 menstrual periods Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 235000021075 protein intake Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 206010012713 Diaphragmatic hernia Diseases 0.000 description 1
- 208000025024 Digestive tract malformation Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000035357 Focal Infection Diseases 0.000 description 1
- 206010070538 Gestational hypertension Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010041273 Sodium imbalance Diseases 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- RRNJROHIFSLGRA-JEDNCBNOSA-N acetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.NCCCC[C@H](N)C(O)=O RRNJROHIFSLGRA-JEDNCBNOSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 235000005550 amino acid supplement Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 201000005890 congenital diaphragmatic hernia Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000005053 encephalomalacia Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000009866 extrahepatic cholestasis Diseases 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 229940083626 folic acid 0.4 mg Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000005337 ground glass Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 210000005008 immunosuppressive cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 229960005357 lysine acetate Drugs 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 230000036630 mental development Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000001123 neurodevelopmental effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- GQTHJBOWLPZUOI-FJXQXJEOSA-M sodium D-pantothenate Chemical compound [Na+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GQTHJBOWLPZUOI-FJXQXJEOSA-M 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 229940068459 sodium pantothenate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the invention belongs to the technical field of nutrition, and specifically relates to neonatal nutrition management, in particular to a special solution for VLBWI nutrition management, and a preparation method and application thereof.
- VLBWI Very low birth weight infants
- VLBWI Very low birth weight infants
- CAI W Parenteral nutrition of newborn[J]. Clin Pediatr, 2004, 22(4): 267-268.
- the incidence of preterm birth and VLBWI has shown a rising trend.
- Epidemiological studies by Law K S and others have pointed out that the incidence of VLBWI in the United Kingdom and the United States was 0.20% in 1985 and 0.57% in 1988. , 1.0% in 2005, 1.2% in 2010, and 1.5% in 2015. Based on this, the hospitalization management of preterm VLBWI has become the focus of the academic community.
- enteral nutrition is a necessary means to ensure nutritional supply and can meet the metabolic and developmental needs of children.
- Intravenous nutrient supply by means of intravenous infusion to input the required nutrients for children, increase the children's nutrient reserves, ensure normal metabolism, and reduce the occurrence of various complications.
- Intravenous nutrition was first applied to neonatal nutrition supply in the 1970s. Its application greatly improved the survival rate of premature infants, especially VLBWI and extremely low birth weight infants (ELBWI). Unanimously affirmed.
- the initial purpose of intravenous nutrition for newborns, especially premature infants, is to promote the growth and development of infants to reach or approach the intrauterine growth rate, which is 14.5g/kg ⁇ d.
- Most premature babies are born suitable for gestational age (AGA), but the growth and development after birth is not ideal, especially when the clinical condition is unstable. In other words, a considerable number of premature babies with AGA at birth become small for gestational age (SGA) children when they are discharged from the hospital.
- EUGR extrauterine growth retardation
- the traditional intravenous nutrition supply program provides glucose supply within 24h, and amino acid and fat milk supply start from 24-48h. This program does not conform to the fetal metabolism, so the effect is not ideal.
- Premature infants, especially very low/ultra-low birth weight infants have serious urine protein loss and increase with the decrease of gestational age. Even if amino acid infusion is given, there will still be protein imbalance.
- people's understanding of intravenous nutrition for preterm infants has also changed. It is no longer limited to reducing the mortality rate, but to optimize the quality of life of children.
- the invention discloses a special solution for nutrition management of VLBWI and a preparation method and application thereof, and discloses that the formulated "special solution” is effective for the intake of nutrients and calorie during the hospitalization of very low birth weight infants (Very low birth weight infant, VLBWI). Weight gain, biochemical indicators, immune function, complications, and treatment outcomes are effectively improved, providing a new program for clinical nutritional management of premature very low birth weight infants.
- the special formulation of the present invention achieves unexpected technical effects: (1) The formulated "special formulation” can obviously promote the growth and development of premature VLBWI, increase the rate of weight gain, shorten the time to restore birth weight and the time for half and full enteral nutrition.
- VLBWI nutrition management special solution its preparation method includes the following steps, fat emulsion, amino acids, glucose, electrolytes, vitamins are mixed under aseptic conditions to obtain VLBWI nutrition management special solution; said fat emulsion is medium and long chain fat emulsion
- vitamins are composed of water-soluble vitamins and fat-soluble vitamins; the electrolyte is sodium chloride, or sodium chloride and potassium chloride.
- the fat emulsion, amino acids, glucose, electrolytes, and vitamins exist in the form of fat emulsion injection, amino acid injection, glucose injection, electrolyte injection, and vitamin injection, respectively; as 100 ml of special preparation for VLBWI nutrition management, Among them, the fat emulsion injection is 5-6 mL, the amino acid injection is 40 mL, the electrolyte injection is 2 mL, the vitamin injection is 1.8-2.5 mL, and the glucose injection is the remainder.
- the vitamin injection is composed of a water-soluble vitamin injection and a fat-soluble vitamin injection in a volume ratio of 1; preferably, the glucose injection is composed of a 10% glucose injection and a 50% glucose injection with a volume ratio of 4:1 composition.
- Example: The preparation method of the special solution for VLBWI nutrition management of the present invention is as follows: electrolyte injection (sodium chloride injection or sodium chloride/potassium chloride injection), glucose injection, amino acid injection, water-soluble vitamin injection Mixing to obtain injection A; mixing fat-soluble vitamin injection and fat emulsion injection to obtain injection B; mixing injection A and injection B to obtain a special preparation for VLBWI nutrition management.
- electrolyte injection sodium chloride injection or sodium chloride/potassium chloride injection
- glucose injection amino acid injection
- water-soluble vitamin injection Mixing to obtain injection A
- mixing fat-soluble vitamin injection and fat emulsion injection to obtain injection B
- mixing injection A and injection B to obtain a special preparation for VLBWI nutrition management.
- the medium and long-chain fat emulsion is a conventional name in the art and is an existing product.
- the fat emulsion injection is a 20% medium and long-chain fat emulsion injection; the present invention uses a combination of medium and long-chain fat emulsions.
- There are clinical nutrient solutions to reduce liver damage and cholestasis have a small effect on plasma free bilirubin, and have a low affinity with plasma albumin. In addition, it has fast oxidation and metabolism and can be cleared from the blood stream faster. After intravenous nutrition, the total bilirubin was significantly lower than the control group, and the degree of jaundice was relatively mild, indicating that the use of the special solution of the present invention is relatively safer for children with hyperbilirubinemia.
- the amino acid is 6.7% of children’s compound amino acids (19AA-I), which is a compound preparation and a sterile aqueous solution prepared from 19 kinds of amino acids. Its composition is 1000ml containing 4.9g of isoleucine and lysine acetate.
- the percentage is the mass percentage.
- the invention also discloses the application of the above-mentioned special solution for VLBWI nutrition management in preparing the VLBWI nutrition management nutrient solution.
- the neonatal intensive care unit (NICU) of the Children’s Hospital of Soochow University was selected from May 2016 to November 2017 in 182 preterm VLBWI cases with birth weight ⁇ 1500g and gestational age ⁇ 37 weeks as the research object, randomized Divided into two groups: a control group and a study group (the present invention), of which 120 cases were in the control group, and NICU implemented existing nutrition management, and the study group was 62 cases in which the nutrition department implemented the special liquid nutrition management for VLBWI nutrition management of the present invention;
- General information of the children in the group the general condition of the prenatal mother, the intake of enteral and parenteral nutrients and calorie on the 7, 14, and 21 days after birth, the rate of weight gain, the 1, 7, 14, and 21 days after birth
- biochemical indicators before discharge immune indicators within one week and two weekends after birth, incidence of complications, disease progression, incidence of extrauterine growth retardation (EUGR) evaluated by weight, length of hospital stay, summary of this Invented the
- 2Cellular immune indicators within one week after birth, there was no significant difference in the levels of CD3 + , CD4 + , CD8 + , CD4 + /CD8 + between the two groups (P>0.05); the study group had CD3 + , CD4 + , The level of CD4 + /CD8 + was significantly higher than that of the control group (P ⁇ 0.05), and there was no significant difference in the level of CD8 + between the two groups (P>0.05).
- Figure 1 shows the selection of research objects
- Figure 2 shows the comparison of the intake of PN and EN nutrients and calories between the two groups on the 7th day after birth
- Figure 3 shows the comparison of the intake of PN and EN nutrients and calories between the two groups on the 14th day after birth
- Figure 4 shows the comparison of the intake of PN and EN nutrients and calories between the two groups on the 21st day after birth, *P ⁇ 0.05;
- Figure 5 shows the comparison of weight gain and intravenous nutrition time between the two groups, *P ⁇ 0.05
- FIG. 6 shows the comparison of liver function related indexes between the two groups, *P ⁇ 0.05
- Figure 7 shows the comparison of protein-related indexes between the two groups, *P ⁇ 0.05
- Figure 8 shows the comparison of electrolyte indexes between the two groups, *P ⁇ 0.05
- FIG. 9 shows the comparison of humoral immunity indexes between the two groups, *P ⁇ 0.05
- Figure 10 is the comparison of the cellular immune indexes between the two groups, *P ⁇ 0.05;
- Figure 11 is the comparison of the incidence of complications between the two groups, *P ⁇ 0.05;
- Figure 12 shows the comparison of clinical treatment outcomes between the two groups, *P ⁇ 0.05.
- a randomized controlled study method was used to collect and compare the clinical data of the children and their mothers during pregnancy: 1General data of the two groups of children: gender, gestational age, birth weight, small-for-gestational age infants, perinatal asphyxia, NRDS, intrauterine infectivity The occurrence of pneumonia and early-onset sepsis. 2The general prenatal conditions of the two groups of pregnant mothers: the age of the pregnant mother, whether cesarean section, whether to use hormones before delivery, whether there is premature rupture of membranes, placenta previa, placental abruption, amniotic fluid pollution, gestational diabetes, high pregnancy Blood pressure, prenatal cholestasis.
- the nutritional status and weight gain of the two groups of children the intake of enteral, parenteral nutrients and calorie, physiological weight loss, weight growth rate, time to regain birth weight, up to 7th, 14th, and 21st days after birth. Half and full enteral nutrition time.
- 4Biochemical indicators of the two groups of children Biochemical indicators on the 1, 7, 14, 21 days after birth and before discharge, including liver function indicators (ALT, ⁇ -GT, total bilirubin, direct bilirubin), protein Related indexes (albumin, prealbumin, globulin), electrolyte related indexes (blood Na + , K + , Ca 2+ ).
- 5Immune indicators of the two groups of children within one week and two weekends after birth, immunoglobulin IgM, IgG, complement C3, C4, T lymphocyte subsets CD3 + , CD4 + , CD8 + , CD4 + /CD8 + levels.
- PNAC parenteral nutrition associated cholestasis
- NEC neonatal necrotizing enterocolitis
- BPD bronchopulmonary dysplasia
- ROP retinopathy of prematurity
- BIPI brain injury in premature infants
- the starting dose of glucose is 4-8mg ⁇ kg -1 ⁇ min -1
- the speed is 1 ⁇ 2mg ⁇ kg -1 ⁇ min -1
- the starting dose of amino acid is 1.5 ⁇ 2.0g ⁇ kg -1 ⁇ d -1
- press 0.5 ⁇ 1.0g ⁇ kg -1 ⁇ d -1
- the speed increases to 3.5 ⁇ 4.0g ⁇ kg -1 ⁇ d -1
- the starting dose of fat emulsion is 1.0g ⁇ kg -1 ⁇ d -1 , and it increases at a speed of 0.5 ⁇ 1.0g ⁇ kg -1 ⁇ d -1
- the total amount does not exceed 3.0g ⁇ kg -1 ⁇ d -1 ; sodium 2.0 ⁇ 3.0mmol ⁇ kg -1 ⁇ d -1 , potassium 1.0 ⁇ 2.0mmol ⁇ kg -1
- PNAC PN time ⁇ 2 weeks, and serum direct bilirubin ⁇ 25.6umol/L, except for extrahepatic cholestasis by abdominal ultrasound or other examinations.
- NEC Two of the following 4 characteristics can be considered for clinical diagnosis: 1Bloating; 2Hematochezia; 3Drowsiness, apnea, hypotonia; 4Intestinal wall gas.
- BPD Premature low birth weight infants, with or without history of mechanical ventilation, oxygen inhalation time ⁇ 28 days (gestational age ⁇ 32 weeks after the last menstrual period) or 36 weeks of gestational age correction (pregnancy after the last menstrual period) Age ⁇ 32 weeks) still needs oxygen therapy.
- Anemia in preterm infants Peripheral venous blood Hb ⁇ 140g/L, Hct ⁇ 0.45 within one week after birth.
- ROP The dividing line between the vascular area and the avascular area of the retina in the early stage of the disease is a clinical sign of ROP. Proliferative lesions at the boundary, abnormal retinal blood vessels, and varying degrees of traction retinal detachment, and late changes should be considered for the diagnosis of ROP.
- Late-onset neonatal sepsis Onset after 7 days of birth, clinical symptoms of infection and poisoning, often focal infections such as umbilitis, pneumonia, or meningitis, changes in peripheral blood, and significantly higher C-reactive protein, may be considered for this disease Diagnosis, the detection of pathogenic bacteria or pathogen antigens in blood culture can confirm the diagnosis.
- BIPI BIPI: Premature infants have different degrees of cerebral ischemia or/and hemorrhagic damage due to various pathological factors before, during or after birth, and the corresponding symptoms and signs of brain injury may appear clinically.
- Early head B-ultrasonography or magnetic resonance imaging can detect severe cerebral edema, various types of intracranial hemorrhage, cerebral infarction, white matter damage and other changes.
- the clinical data results are all expressed in measurement or count data, and the measurement data is in line with the normal distribution and adopts the mean ⁇ standard deviation Indicates that the comparison between the two groups uses the t test; the measurement data does not meet the normal distribution using P50 (P25, P75), and the comparison between the two groups uses the rank sum test; the count data is expressed as a percentage, and the comparison between the two groups uses the chi-square test.
- P ⁇ 0.05 considered the difference to be statistically significant.
- the preparation method of the special formulation for VLBWI nutrition management of the present invention is as follows.
- the fat emulsion, amino acids, glucose, electrolytes, and vitamins are mixed under aseptic conditions to obtain the special formulation for VLBWI nutrition management;
- the chain fat emulsion is composed of;
- the vitamins are composed of water-soluble vitamins and fat-soluble vitamins;
- the electrolyte is sodium chloride or is composed of sodium chloride and potassium chloride. All medicaments are commercially available products.
- VLBWI nutrition management special solution 100ml containing: 6.7% children's compound amino acid (19AA-1) 40ml, 20% medium and long-chain fat emulsion 6ml, 10% sodium chloride injection 1ml, 10% potassium chloride injection 1ml, 50% glucose injection 10ml, 10% glucose injection 40ml, water-soluble vitamin injection for injection 1ml, fat-soluble vitamin injection 1ml (no potassium added within three days after birth); preparation method: 1 10% sodium chloride, 10% potassium chloride, 50% glucose injection, 6.7% children's compound amino acid (19AA-1), water-soluble vitamins for injection are added to 10% glucose injection successively; 2Inject the fat-soluble vitamins into 20% medium and long-chain fat emulsion 3Inject the nutrient solution prepared in step 2 into the nutrient solution prepared in step 1, and mix thoroughly to obtain a special solution for VLBWI nutrition management, which is used in the following research groups.
- the intravenous nutrition program for the control group was formulated by the NICU Department of the Children’s Hospital of Soochow University. It is mainly an agreed formula PN: total liquid volume 1473.4ml, containing 20% fat emulsion 250ml, 6.7% pediatric compound amino acid 500ml, 50% glucose 200ml, 10% Glucose 500ml, 10% sodium chloride injection 6.7ml, 10% potassium chloride injection 6.7ml, fat-soluble vitamin injection (II) (vitalipid) 10ml, of which the fat emulsion is long-chain fat emulsion (LCT) ), the insufficient amount of liquid is supplemented by a mixed liquid of glucose and amino acids.
- PN total liquid volume 1473.4ml, containing 20% fat emulsion 250ml, 6.7% pediatric compound amino acid 500ml, 50% glucose 200ml, 10% Glucose 500ml, 10% sodium chloride injection 6.7ml, 10% potassium chloride injection 6.7ml, fat-soluble vitamin injection (II) (vitalipid) 10
- the amino acid injection is a 6.7% pediatric compound amino acid aqueous solution; the water-soluble vitamin injection is a hydrolevita compound preparation; the fat-soluble vitamin injection is a vitamin compound preparation.
- each medicament is injection, and the percentages are all mass percentages.
- the raw materials involved in the present invention are all conventional commercially available products.
- the inventiveness of the present invention is to limit the proportions and formulas of these conventional raw materials to obtain a new special solution.
- the nutrients are more abundant and comprehensive, and the bioavailability is high. It can effectively promote premature VLBWI to catch up with growth.
- the gestational age was 26 weeks +6 -35 weeks +4 , with an average of (31.05 ⁇ 1.79) weeks; the birth weight was between 1.0kg-1.44kg, with an average of (1.28 ⁇ 0.23). )kg; 11 cases of small for gestational age, 14 cases of perinatal asphyxia, 19 cases of NRDS, 39 cases of intrauterine infectious pneumonia, and 3 cases of early-onset sepsis. There were no significant differences between the two groups in gender, gestational age, birth weight, small-for-gestational age infants, intrapartum asphyxia, NRDS, intrauterine infectious pneumonia, and early-onset sepsis (P>0.05), see Table 1 for details.
- t 1 and P 1 are the comparison results of the two groups of PN
- t 2 , P 2 are the comparison results of the two groups of EN.
- t 1 and P 1 are the comparison results of the two groups of PN
- t 2 , P 2 are the comparison results of the two groups of EN.
- t 1 and P 1 are the comparison results of the two groups of PN
- t 2 , P 2 are the comparison results of the two groups of EN.
- PN parenteral nutrition
- EN enteral nutrition
- preterm infants are only given intravenous nutrition early after birth, and given to preterm infants when the condition is stable Milk feeding, that is, both groups have both PN and EN.
- the two groups are different in intravenous nutrition (PN).
- the control group injected the intravenous nutrient solution agreed by the hospital, which is likely to cause relatively insufficient nutrients.
- the study group injected the special formula of the present invention Liquid, nutrients are comprehensive, and the ratio is more refined.
- Very low birth weight infants are basically premature infants. Various organs are underdeveloped, poor adaptability, and low survival rate. Issues that need to be paid attention to after birth include warmth, NRDS, respiratory and circulatory support, intravenous nutrition, infection, intracranial hemorrhage , Jaundice, electrolyte disorders, etc. Intravenous nutrition is an important part of premature infants, especially very low/ultra-low birth weight infants, during NICU treatment. VLBWI of premature birth is extremely low weight, slow growth, and high mortality rate.
- the mortality rate of newborns is about 1.2%, and the mortality rate of preterm infants is between 12.7%-20.8%, while the mortality rate of VLBWI is higher; given to premature infants,
- adequate nutritional support and respiratory and circulatory support in the early stage of VLBWI are very important, and even the concept of "nutrition first aid" is proposed, which believes that the nutritional status of the body directly affects the original effects of drugs and devices, and determines the survival of the body and the survival of the body. Quality of Life. Therefore, early "active" nutritional support is advocated at home and abroad to promote catch-up growth in the early postnatal period and reduce the occurrence of EUGR.
- VLBWI nutrition guidelines for preterm birth all suggest the need to give higher nutrients and calories, but clinical practice is often affected by many factors and the supply fails to meet its needs.
- a multi-center study of preterm birth in the Pearl River Delta of Guangdong province reported that the median energy intake on the first, second, and fourth week after birth in the EUGR group was 55kcal/(kg ⁇ d), 73kcal/(kg ⁇ d), 92kcal, respectively /(kg ⁇ d), the non-EUGR group was 56kcal/(kg ⁇ d), 81kcal/(kg ⁇ d), 96kcal/(kg ⁇ d), EUGR group and non-EUGR group did not meet the recommended standards for preterm infants.
- the weight gain is more ideal, and the time to restore birth weight is shorter. It is helpful to the establishment of intestinal feeding.
- Water-soluble vitamins are the components of dozens of coenzymes in the body. , Division of labor and collaboration in the metabolism of the three major nutrients, with the use of other nutrients, improve the overall effect of nutritional supply, and ultimately improve the growth and development of newborns.
- the nutrients in the "special solution" of the present invention are more abundant and reasonable, which can meet the energy and nutrition requirements of VLBWI during growth, ensure the growth rate of body weight, promote the establishment of enteral nutrition, and achieve full enteral nutrition as soon as possible, while reducing The incidence of EUGR.
- t 1 and P 1 are the comparison results of the two groups on the first day after birth
- t 2 and P 2 are the comparison results on the 7th day after birth
- t 3 and P 3 are the comparison results on the 14th day after birth
- t 4 is the comparison result on the 21st day after birth
- t 5 and P 5 are the comparison results before discharge.
- t 1 and P 1 are the comparison results of the two groups on the first day after birth
- t 2 and P 2 are the comparison results on the 7th day after birth
- t 3 and P 3 are the comparison results on the 14th day after birth
- t 4 is the comparison result on the 21st day after birth
- t 5 and P 5 are the comparison results before discharge.
- t 1 and P 1 are the comparison results of the two groups on the first day after birth
- t 2 and P 2 are the comparison results on the 7th day after birth
- t 3 and P 3 are the comparison results on the 14th day after birth
- t 4 is the comparison result on the 21st day after birth
- t 5 and P 5 are the comparison results before discharge.
- LCT Soybean oil
- the ALT, ⁇ -GT, and direct bilirubin of the present invention are significantly lower than those of the control group, indicating that the special solution of the present invention reduces liver damage and cholestasis compared with the existing clinical nutrient solutions; MCT has a lower effect on plasma free bilirubin The effect is small, the affinity to plasma albumin is low, and its oxidative metabolism is fast, and it can be removed from the blood stream quickly.
- the total bilirubin in the study group was significantly lower than that in the control group, and the degree of jaundice was relatively mild. It indicates that children with hyperbilirubinemia are relatively safer to use the special solution of the present invention.
- the two groups of premature infants of the present invention had no significant difference in the amount of amino acids during early intravenous nutrition, but after intravenous nutrition, the albumin, prealbumin, and globulin levels of the study group were higher than those of the control group, and prealbumin was 7 days after birth That is to say, there are differences, its half-life is short, and changes are more sensitive, indicating that the "special liquid” has a finer ratio of various nutrients, a stronger synergistic effect, and is more conducive to the utilization of amino acids. It is rich in fat-soluble vitamins and water-soluble vitamins. An important coenzyme in the process of amino acid metabolism can effectively promote protein synthesis and metabolism, so that the newborn can have a certain protein reserve in the body.
- the blood K + of the two groups of premature infants of the present invention both increased to varying degrees on the 7th and 14th days after birth.
- the blood K + level of the "special solution" in the study group was also significantly higher than that in the control group.
- VLBWI was often associated with hypocalcemia.
- the two groups of premature infants of the present invention showed a decrease in blood Ca 2+ level on the 7th day after birth, and then gradually increased, but the blood Ca 2+ level of the study group was always significantly higher than that of the control group. It shows that the vitamin composition of the special solution of the invention is reasonable and directly affects the blood Ca 2+ level.
- C3 and C4 are the body's most important complements.
- the components and cleavage fragments of C3 are the core of the complement system.
- C4 is the main component in the complement activation process and plays an important role in the activation of the classical pathway. .
- immunoglobulins IgG is the main body's anti-infection antibody, but its self-synthesis is slow and the synthesis amount is very small.
- IgM is an immunoglobulin that appears in the early stage of the initial humoral immune response. Its effect is stronger than IgG, and it is the first to be synthesized and secreted. antibody.
- t 1 and P 1 are the comparison results before and after the control group
- t 2 and P 2 are the comparison results before and after the study group
- t 3 and P 3 are the comparison results within one week after birth between the two groups
- t 4 and P 4 are the two groups Comparing the results during the two weekends after the birth.
- CD3 + in T lymphocytes is a characteristic indicator, that is, the total number of T lymphocytes, which can be divided into two subgroups of CD4 + and CD8 + cells.
- CD4 + is an immunoregulatory cell
- CD8 + is an immunosuppressive cell.
- the CD3 + , CD4 + , CD8 + , and CD4 + /CD8 + levels of the two groups of premature infants were equal, and the difference was not statistically significant (P>0.05).
- the two groups of children had CD3 + , CD4 + , CD4 + /CD8 + increase, and CD8 + decrease within one week after birth.
- the comparison of the two groups’ indicators before and after were statistically significant.
- t 1 and P 1 are the comparison results before and after the control group
- t 2 and P 2 are the comparison results before and after the study group
- t 3 and P 3 are the comparison results within one week after birth between the two groups
- t 4 and P 4 are the two groups Comparing the results during the two weekends after the birth.
- VLBWI Premature VLBWI leaves the mother prematurely, the immune system and functions are not yet mature, and the immunity is poor.
- Optimizing immune function and enhancing own immunity are of great value for improving the growth and development of premature VLBWI.
- the body's immune system mainly depends on the subgroups of B lymphocytes, complement and T lymphocytes. The better the effect, the better the immune function of the newborn.
- the influence of fat emulsion on immune function has attracted much attention. In the past, it was believed that fat emulsion would affect the immune function of newborns. In the special formulation of the present invention, the fat emulsion can effectively reduce the damage to the immune function of the body.
- the level of arachidonic acid and arachidonic acid is lower, the production of prostaglandin E2 is reduced, and the content of linoleic acid and arachidonic acid is lower, which can reduce the formation of prostaglandin E2, thereby reducing immunosuppression.
- the fat in the blood Milk clearance is fast, the load of the reticuloendothelial system is low, and the immune function is small.
- the invention pays attention to the cooperation of vitamins to improve the immunity of premature infants; therefore, it has little effect on the immune function of newborns.
- zone 1 ROP Insufficient nutritional intake is prone to zone 1 ROP, and the growth rate is slow. Any ROP including zone 1 ROP can occur.
- the weight gain rate of the children in the study group of the present invention is faster than that of the control group, and the incidence of ROP is lower than that of the control group, indicating that a rich and reasonable nutrient ratio can reduce the occurrence of ROP to a certain extent .
- the early nutritional status of premature VLBWI not only affects the recent growth and development, but also has an irreversible long-term effect on the development of the nervous system.
- the protein reserves in the biochemical indicators of the study group of the present invention are higher than those of the control group, and the incidence of BIPI is lower than that of the control group.
- the higher availability of amino acids helps to promote the early development of the nervous system in premature infants and reduce the risk of BIPI; active protein support can significantly improve the long-term growth and neurodevelopmental prognosis of premature infants, and can increase the utilization of nitrogen, which is effective Promote the neurodevelopment of premature infants and reduce the occurrence of brain damage in premature infants such as intracranial hemorrhage and white matter softening.
- the functions of the various systems of preterm VLBWI are not yet mature, and complications occur frequently, and the demand for nutrition is large, but it cannot be met by feeding. Therefore, intravenous nutrition is the main early nutrition method.
- the "special liquid" nutrient is more accurate and comprehensive, the ratio is more reasonable, and the utilization rate is higher. It is more in line with the requirements of preterm VLBWI for nutrients and energy. It is conducive to promoting growth and development, optimizing biochemical indicators, improving liver function, replenishing protein, and balancing electrolytes. Enhances cellular immune function, is safe and effective, shortens the hospital stay, and reduces the incidence of EUGR; especially the clinical results show that the special solution of the present invention not only reduces the mortality rate, but also optimizes the quality of life of premature infants.
- the "special liquid” of the present invention has richer and more comprehensive nutrients, high bioavailability, can effectively promote preterm VLBWI to catch up with growth, increase the rate of weight gain, shorten the time to restore birth weight, reach half and full enteral nutrition, optimize biochemical indicators, and improve liver Function, balance electrolytes, and basically will not cause adverse effects on the immune system, but can improve cellular immune function to a certain extent, reduce the incidence of complications such as PNAC, NEC, BPD, hypoglycemia, ROP, late-onset sepsis, BIPI, etc. The effect is ideal and the clinical application value is high.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
一种VLBWI营养管理用特配液,其特征在于:将脂肪乳剂、氨基酸、葡萄糖、电解质、维生素在无菌条件下混合得到;脂肪乳剂为中长链脂肪乳剂;该特配液为临床对早产极低出生体重儿的营养管理提供了新方案。该特配液可以降低PNAC、NEC、BPD、低血糖、ROP、晚发型败血症、BIPI的发生率,安全性好,同时可以降低EUGR的发生率,缩短住院时间,优化患儿生命质量。
Description
本发明属于营养技术领域,具体涉及新生儿营养管理,尤其涉及VLBWI营养管理用特配液及其制备方法与应用。
极低出生体重儿(Very low birth weight infant,VLBWI)即出生体重<1500g的新生儿,因其各项脏器功能发育极不成熟,易发生各种并发症,无法适应外界环境,死亡率较高(CAI W.Parenteral nutrition of newborn[J].Clin Pediatr,2004,22(4):267-268)。近年来随着生殖技术及新生儿重症监护的发展,早产、VLBWI发生率呈现不断上升趋势,Law K S等的流行病学研究指出英美国家1985年VLBWI发生率为0.20%,1988年为0.57%,2005年为1.0%,2010年为1.2%,2015年为1.5%。基于此,早产VLBWI的住院管理成为学界关注的重点。
早产VLBWI胃肠道功能发育不全,吮吸及吞咽功能不协调,早期很难实行肠内营养(Enteral nutrition,EN)供应(Qiu-Li B U.Effect of early enteral nutrition and total parenteral nutrition on postoperative patients with esophageal carcinoma[J].Journal of Qiqihar University of Medicine,2015),予以静脉营养为保证营养供应的必要手段,能够满足患儿的代谢及发育需要。静脉营养供应,以静脉输注方式为患儿输入所需营养成分,增加患儿营养储备,保证正常代谢所需,减少各种并发症的发生。
静脉营养方案最初应用于新生儿营养供应中是在20世纪70年代,其应用极大地提升了早产儿、尤其是VLBWI和超低出生体重儿(Extremely low birth weight infant,ELBWI)的存活率,受到一致肯定。新生儿尤其是早产儿静脉营养最初目的是促进患儿生长发育,使其达到或接近宫内生长速度,即14.5g/kg·d。大多数早产儿出生时是适于胎龄儿(Appropriate for gestational age,AGA),但出生后的生长发育情况却并不理想,特别是临床病情不稳定时。也就是说,有相当一部分出生时AGA的早产儿在出院时变成了小于胎龄(Small for gestational age ,SGA)儿,此类患儿必然经历追赶生长的过程,但追赶生长的时间窗口却相当狭窄。2003年国外学者Clark提出宫外生长发育迟缓(EUGR)概念,将出生后生长发育计量指标低于同胎龄宫内生长速率期望值的第10百分位(生长曲线的第10百分位)定义为EUGR,并指出降低EUGR发生率,是提升婴儿生命质量的关键。此后Cooke等提出EUGR的发生率与早产儿出生一周内的营养摄入量有关,营养摄入量越多,EUGR的发生率越低。营养充足,营养素全面,患儿自身免疫力强,能够应对外界环境的适应能力,降低并发症发生率,进而促进生长发育。Stephens等研究者以早产儿为研究对象,对蛋白质、能量摄入量与早产儿生后18月龄智力发展关系进行分析,指出早产儿出生后蛋白质、能量的摄入量与其智力呈正相关。蛋白质及能量摄入不足、脂肪乳应用受限是导致早产儿智力发育差的根本原因。EUGR是NICU(新生儿重症监护室)中常见问题。国外学者L.Bejstová等对NICU早产儿进行调查分析,研究发现营养策略差异是导致NICU早产儿营养不良,生长滞后的重要原因。
发明概述
传统的静脉营养供应方案于24h内予以葡萄糖供应,于24-48h开始予以氨基酸、脂肪乳供应,这种方案并不符合胎儿的代谢规律,因此效果并不理想。早产儿,尤其是极低/超低出生体重儿,尿蛋白丢失严重,且会随着胎龄的降低而增加,即使予以氨基酸输注液,仍会有蛋白质失衡现象。随着对早产儿认识的不断加深,人们对早产儿静脉营养的认识也发生了改变,不再局限于降低病死率,而是更要优化患儿生命质量。
问题的解决方案
本发明公开了VLBWI营养管理用特配液及其制备方法与应用,公开了配制的“特配液”对早产极低出生体重儿(Very low birth weight infant,VLBWI)住院期间营养素及热卡摄入、体重增长、生化指标、免疫功能、并发症、治疗结局有效改善,为临床对早产极低出生体重儿的营养管理提供新方案。本发明特配液 取得意想不到的技术效果:(1)配制的“特配液”能够明显促进早产VLBWI生长发育,提升体重增长速率,缩短恢复出生体重时间及达半量、全量肠内营养时间。(2)予以早产VLBWI“特配液”静脉营养方案能够优化生化指标,改善肝功能,补充蛋白质,平衡电解质。(3)予以早产VLBWI“特配液”静脉营养方案对体液免疫影响较小,能改善细胞免疫,有助于提升早产VLBWI的免疫功能。(4)予以早产VLBWI“特配液”可以降低PNAC、NEC、BPD、低血糖、ROP、晚发型败血症、BIPI的发生率,安全性好,同时可以降低EUGR的发生率,缩短住院时间,优化患儿生命质量。
本发明采用如下技术方案:
VLBWI营养管理用特配液,其制备方法包括以下步骤,将脂肪乳剂、氨基酸、葡萄糖、电解质、维生素在无菌条件下混合,得到VLBWI营养管理用特配液;所述脂肪乳剂为中长链脂肪乳剂;所述维生素由水溶性维生素以及脂溶性维生素组成;所述电解质为氯化钠,或者氯化钠和氯化钾。
本发明中,脂肪乳剂、氨基酸、葡萄糖、电解质、维生素分别以脂肪乳剂注射液、氨基酸注射液、葡萄糖注射液、电解质注射液、维生素注射液形式存在;以100毫升VLBWI营养管理用特配液计,其中脂肪乳剂注射液为5~6mL,氨基酸注射液为40mL,电解质注射液为2mL,维生素注射液为1.8~2.5mL,葡萄糖注射液为余量。优选的,维生素注射液由体积比为1的水溶性维生素注射液以及脂溶性维生素注射液组成;优选的,葡萄糖注射液由体积比为4∶1的10%葡萄糖注射液、50%葡萄糖注射液组成。
例:本发明VLBWI营养管理用特配液的制备方法如下:将电解质注射液(氯化钠注射液或者氯化钠/氯化钾注射液)、葡萄糖注射液、氨基酸注射液、水溶性维生素注射液混合得到注射液A;将脂溶性维生素注射液、脂肪乳剂注射液混合得到注射液B;混合注射液A与注射液B,得到VLBWI营养管理用特配液。
本发明中,中长链脂肪乳剂为本领域常规名称,为现有产品,优选脂肪乳剂注射液为20%中长链脂肪乳剂注射液;本发明将中长链脂肪乳剂组合使用,相较现有临床营养液降低肝功能损害、胆汁淤积,对血浆游离胆红素的影响较小,与血浆白蛋白的亲和力较低,加之其氧化代谢快,能较快从血流中清除,研究组 经静脉营养后总胆红素明显低于对照组,黄疸程度相对较轻,说明高胆红素血症患儿使用本发明特配液相对更安全。
本发明中,氨基酸为6.7%的小儿复方氨基酸(19AA-I),为复方制剂,由19种氨基酸配制而成的灭菌水溶液,其组份为每1000ml含异亮氨酸4.9g、醋酸赖氨酸4.9g、苯丙氨酸7.9g、色氨酸1.2g、半胱氨酸<0.2g、酪氨酸1.4g、精氨酸7.3g、丝氨酸2.3g、谷氨酸3.0g、牛磺酸0.15g、亮氨酸8.4g、甲硫氨酸2.0g、苏氨酸2.5g、缬氨酸4.7g、组氨酸2.9g、丙氨酸3.2g、脯氨酸4.1g、门冬氨酸1.9g、甘氨酸2.2g;水溶性维生素注射液为水乐维复方制剂,规格为10ml/瓶,每瓶组份为硝酸硫胺3.1mg,核黄素磷酸钠4.9mg,烟酰胺40mg,盐酸吡多辛4.9mg,泛酸钠16.5mg,维生素C钠113mg,生物素60ug,叶酸0.4mg,维生素B
125.0ug,辅料为甘氨酸、乙二胺四醋酸二钠;脂溶性维生素注射液为维他利匹特复方制剂,规格为10ml/支,每支中组份为维生素A0.99mg,维生素D
25ug,维生素E9.1mg,维生素K
10.15mg,辅料为注射用大豆油,注射用卵磷脂、甘油和注射用水。
本发明中,百分数为质量百分数。
本发明还公开了上述VLBWI营养管理用特配液在制备VLBWI营养管理营养液中的应用。
以苏州大学附属儿童医院新生儿重症监护室(Neonatal intensive care unit,NICU)2016年5月-2017年11月收治的182例出生体重<1500g、胎龄<37周的早产VLBWI为研究对象,随机分为对照组、研究组(本发明)两组,其中对照组120例,由NICU实施现有营养管理,研究组62例,由营养科实施本发明VLBWI营养管理用特配液营养管理;对比两组患儿一般资料,产前孕母一般情况,生后第7、14、21天肠内及肠外营养素及热卡摄入情况,体重增长速率,生后第1、7、14、21天及出院前生化指标,生后一周内及两周末免疫指标,并发症发生率,疾病转归情况、以体重评价的宫外生长发育迟缓(Extrauterine growth retardation,EUGR)发生率、住院时间,总结本发明VLBWI营养管理用特配液对早产VLBWI住院期间管理的有益效果。
发明的有益效果
(1)两组一般情况比较:两组在性别、胎龄、出生体重、小于胎龄儿、新生儿呼吸窘迫综合征(Neonatal respiratory distress syndrome,NRDS)、宫内感染性肺炎、产时窒息情况比较差异均不显著(P>0.05)。(2)两组产前孕母一般情况比较:孕母年龄、剖宫产、产前使用激素、胎膜早破、前置胎盘、胎盘早剥、羊水污染、妊娠期糖尿病、妊娠期高血压、产前胆汁淤积在两组间差异均无统计学意义(P>0.05)。(3)两组营养情况比较:生后第7、14天,两组营养素及热卡摄入差异均不显著(P>0.05);生后第21天,研究组肠外营养(Parenteral nutrition,PN)营养素及热卡摄入均低于对照组,肠内营养(Enteral nutrition,EN)营养素及热卡摄入高于对照组(P<0.05)。(4)两组体重增长情况比较:两组生理性体重下降幅度差异不显著(P>0.05),研究组恢复出生体重时间、达半量及全量肠内营养时间均较对照组短,而体重增长速率高于对照组(均P<0.05)。(5)两组生化指标比较:①肝功能指标:生后第1天,两组间谷丙转氨酶(Alanine aminotransferase,ALT)、γ-GT、总胆红素、直接胆红素水平无显著差异(P>0.05);出生后第7、14、21天及出院前,研究组γ-GT、总胆红素、直接胆红素均明显低于对照组(P<0.05);研究组ALT于生后第7、14、21天显著低于对照组(P<0.05)。②蛋白质指标:两组患儿生后第1天白蛋白、前白蛋白、球蛋白水平无显著差异(P>0.05)。生后第7天,研究组前白蛋白水平高于对照组(P<0.05),生后第14、21天及出院前,研究组白蛋白、前白蛋白、球蛋白水平均明显高于对照组(P<0.05)。③电解质指标:生后第1天两组血Na
+、K
+、Ca
2+水平无显著差异(P>0.05)。生后第7、14、21天及出院前,两组血Na
+水平无显著差异(P>0.05),而研究组血Ca
2+显著高于对照组(P<0.05)。血K
+于生后第7、14天研究组高于对照组(P<0.05)。(6)免疫功能指标比较:①体液免疫指标:生后一周内,两组新生儿的C3、C4、IgM、IgG水平无显著差异(P>0.05);生后两周末,研究组C3、IgG水平明显高于对照组(P<0.05),C4、IgM两组间差异不显著(P>0.05)。②细胞免疫指标:生后一周内,两组间CD3
+、CD4
+、CD8
+、CD4
+/CD8
+水平无显著差异(P>0.05);生后两周末,研究组CD3
+、CD4
+、CD4
+/CD8
+水平明显高于对照组(P<0.05) ,两组间CD8
+水平无显著差异(P>0.05)。(7)两组并发症情况比较:研究组肠外营养相关性胆汁淤积症(Parenteral nutrition associated cholestasis,PNAC)、坏死性小肠结肠炎(Necrotizing enterocolitis,NEC)、支气管肺发育不良(Bronchopulmonary dysplasia,BPD)、低血糖、早产儿视网膜病(Retinopathy of prematurity,ROP)、晚发型败血症、早产儿脑损伤(Brain injury in premature infants,BIPI)发生率低于对照组(P<0.05);(8)两组临床治疗结局情况比较:与对照组相比,研究组EUGR发生率明显低、住院时间明显短(P<0.05)。
对附图的简要说明
图1为研究对象的选择;
图2为两组生后第7天PN和EN营养素、热卡摄入比较;
图3为两组生后第14天PN和EN营养素、热卡摄入比较;
图4为两组生后第21天PN和EN营养素、热卡摄入比较,*P<0.05;
图5为两组体重增长、静脉营养时间比较,*P<0.05;
图6为两组肝功能相关指标比较,*P<0.05;
图7为两组蛋白质相关指标比较,*P<0.05;
图8为两组电解质指标比较,*P<0.05;
图9为两组体液免疫指标对比,*P<0.05;
图10为两组细胞免疫指标比较,*P<0.05;
图11为两组并发症发生率比较,*P<0.05;
图12为两组临床治疗结局比较,*P<0.05。
发明实施例
1.研究对象及分组
以2016年5月-2017年11月苏州大学附属儿童医院NICU收治的182例早产VLBWI为研究对象,根据患儿采用不同静脉营养方案将研究对象随机分为对照组(院协定配方+氨基酸补充混合液,为最接近现有技术)和研究组(本发明VLBWI营养管理用特配液)。征得家长知情同意,并通过苏州市儿童伦理委员会批准。
2.纳入标准
(1)1.0kg≤出生体重<1.5kg;
(2)出生24h内转入NICU治疗的早产儿;
(3)静脉营养时间>2周;
(4)病史及临床资料完整者;
(5)家属对本研究知情,自愿接受研究,且能够积极配合。
研究对象的选择见图1。
3.排除标准
(1)合并有先天性遗传代谢疾病;
(2)合并遗传代谢性疾病、严重的先天性心脏病、消化道畸形;
(3)未完成静脉营养提前出院;
(4)无完整的孕产资料;
(5)家属排斥研究。
4.研究方法
采用随机对照研究方法,收集患儿及母孕期临床资料记录并对比:①两组患儿的一般资料:性别、胎龄、出生体重、小于胎龄儿、产时窒息、NRDS、宫内感染性肺炎、早发型败血症发生情况。②两组孕母产前一般情况:孕母年龄、是否剖宫产、产前是否使用激素,有无胎膜早破、前置胎盘、胎盘早剥、羊水污染、妊娠期糖尿病、妊娠期高血压、产前胆汁淤积。③两组患儿营养情况及体重增长情况:生后第7、14、21天肠内、肠外营养素及热卡摄入情况、生理性体重下降幅度、体重增长速率、恢复出生体重时间、达半量及全量肠内营养时间。④两组患儿生化指标:生后第1、7、14、21天及出院前各项生化指标,包括肝功能指标(ALT、γ-GT、总胆红素、直接胆红素)、蛋白质相关指标(白蛋白、前白蛋白、球蛋白)、电解质相关指标(血Na
+、K
+、Ca
2+)。⑤两组患儿免疫指标:生后一周内、两周末,免疫球蛋白IgM、IgG,补体C3、C4,T淋巴细胞亚群CD3
+、CD4
+、CD8
+、CD4
+/CD8
+水平。⑥两组患儿并发症:是否合并肠外营养相关性胆汁淤积症(Parenteral nutrition associated cholestasis,PNAC)、新生儿坏死性小肠结肠炎(Necrotizing enterocolitis,NEC)、支气管肺发育不 良(Bronchopulmonary dysplasia,BPD)、低血糖、贫血、早产儿视网膜病变(Retinopathy of prematurity,ROP)、晚发型新生儿败血症、早产儿脑损伤(Brain injury in premature infants,BIPI)。⑦两组患儿临床治疗结局:出院时病情转归情况、以体重评价的EUGR发生率、住院时间。
两组静脉营养输液原则遵循2013年《中国新生儿营养支持临床应用指南》:葡萄糖开始剂量为4~8mg·kg
-1·min
-1,按1~2mg·kg
-1·min
-1的速度逐渐增加,最大剂量不超过11~14mg·kg
-1·min
-1;氨基酸起始剂量为1.5~2.0g·kg
-1·d
-1,按0.5~1.0g·kg
-1·d
-1速度增加,至3.5~4.0g·kg
-1·d
-1;脂肪乳起始剂量为1.0g·kg
-1·d
-1,按0.5~1.0g·kg
-1·d
-1的速度增加,总量不超过3.0g·kg
-1·d
-1;钠2.0~3.0mmol·kg
-1·d
-1,钾1.0~2.0mmol·kg
-1·d
-1。
5.相关诊断或判定标准
(1)PNAC:PN时间≥2周,且血清直接胆红素≥25.6umol/L,腹部B超或其他检查除外肝外胆汁淤积。
(2)NEC:下列4项特征具备两项可考虑临床诊断:①腹胀;②便血;③嗜睡、呼吸暂停、肌张力低下;④肠壁积气。
(3)BPD:(1)早产低出生体重儿,有或无机械通气治疗史,吸氧时间≥28天(末次月经后孕龄≥32周)或到纠正胎龄36周(末次月经后孕龄<32周)仍需要氧疗。(2)伴有持续性或进行性呼吸功能不全。(3)肺部典型X线或CT表现(双肺纹理增强,透过度减低,呈毛玻璃样,局限性肺气肿或囊腔样改变)。(4)排除先天性心脏病、气胸、胸腔积液及膈疝等疾病。
(4)低血糖症:不论胎龄和日龄,血糖<2.2mmol/L。
(5)早产儿贫血:生后一周内外周静脉血Hb<140g/L,Hct<0.45。
(6)ROP:病变早期在视网膜的有血管区和无血管区之间出现分界线是ROP临床特有体征。分界处增生性病变,视网膜血管走行异常,以及不同程度的牵拉性视网膜脱离,和晚期改变,应考虑ROP诊断。
(7)晚发型新生儿败血症:出生7天后起病,临床有感染中毒症状,常有脐炎、肺炎或脑膜炎等局灶性感染,外周血象改变、C反应蛋白明显增高等可考虑本 病诊断,血培养检测出病原菌或病原菌抗原可确诊。
(8)BIPI:由于产前、产时或/和出生后的各种病理因素导致早产儿不同程度的脑缺血或/和出血性损害,可在临床上出现脑损伤的相应症状和体征,头颅B超或磁共振检查早期可发现严重脑水肿、各种类型的颅内出血、脑梗死、脑白质损伤等改变,晚期均可见多囊脑软化、脑空洞、脑穿通畸形、严重脑室扩张或脑积水及脑萎缩等改变。
(9)早产儿出院转归判定标准:①治愈标准:生命体征稳定,急性期并发症已治愈,体重增长速度稳定在10~30g/d,且已>2000g,已停止用药及吸氧一段时期,经口摄奶量能够满足基本生理需要量。②好转标准:生命体征相对稳定,危及生命的并发症基本控制,体重、摄奶量尚未达到理想标准。③死亡:经积极抢救治疗,病情无好转,没有自主呼吸,心跳停止,心电图示未见心脏电活动。
6.统计学方法
采用SPSS21.0统计学软件处理数据,临床资料结果均以计量或计数资料表示,计量资料中符合正态分布采用均数±标准差
表示,两组间比较采用t检验;计量资料中不满足正态分布采用P50(P25,P75)表示,两组间比较采用秩和检验;计数资料采用百分比表示,两组比较采用卡方检验,P<0.05认为差异有统计学意义。
本发明VLBWI营养管理用特配液的制备方法如下,将脂肪乳剂、氨基酸、葡萄糖、电解质、维生素在无菌条件下混合,得到VLBWI营养管理用特配液;所述脂肪乳剂由中链脂肪乳剂以及长链脂肪乳剂组成;所述维生素由水溶性维生素以及脂溶性维生素组成;所述电解质为氯化钠或者,由氯化钠、氯化钾组成。所有药剂都为市售产品。
实施例
VLBWI营养管理用特配液100ml,包含:6.7%的小儿复方氨基酸(19AA-1)40ml、20%中长链脂肪乳剂6ml、10%氯化钠注射液1ml、10%氯化钾注射液1ml、50%葡萄糖注射液10ml、10%葡萄糖注射液40ml、注射用水溶性维生素注射液1ml 、脂溶性维生素注射液1ml(生后三天内不加钾);制备方法为:①将10%氯化钠、10%氯化钾、50%葡萄糖注射液、6.7%的小儿复方氨基酸(19AA-1)、注射用水溶性维生素先后加入10%葡萄糖注射液;②将脂溶性维生素注入20%中长链脂肪乳剂中;③将步骤②配制的营养液注入步骤①配制的营养液中,充分混合,得到VLBWI营养管理用特配液,用于以下研究组。
对照组静脉营养方案由苏州大学附属儿童医院NICU科室制定,主要是协定配方PN:总液量1473.4ml,包含20%的脂肪乳250ml、6.7%的小儿复方氨基酸500ml、50%葡萄糖200ml、10%葡萄糖500ml、10%氯化钠注射液6.7ml、10%氯化钾注射液6.7ml、脂溶性维生素注射液(II)(维他利匹特)10ml,其中脂肪乳为长链脂肪乳(LCT),不足液体量由葡萄糖及氨基酸混合液体补充。
氨基酸注射液为6.7%的小儿复方氨基酸水溶液;水溶性维生素注射液为水乐维他复方制剂;脂溶性维生素注射液为维他利匹特复方制剂。
研究组、对照组营养液中,各药剂都是注射液,其中百分数均为质量百分数。
本发明涉及的原料都是常规市售产品,本发明的创造性在于将这些常规原料进行比例以及配方的限定得到新的特配液,营养素更丰富全面,生物利用度高,能够有效促进早产VLBWI追赶生长,提高体重增长速率,缩短恢复出生体重时间、达半量及全量肠内营养时间,优化生化指标,改善肝功能,平衡电解质,且基本不会对免疫系统造成不良影响,反而在一定程度上能够提升细胞免疫功能,降低PNAC、NEC、BPD、低血糖、ROP、晚发型败血症、BIPI等并发症发生率,效果理想,临床应用价值高。
本发明有益效果分析:
1.两组一般资料比较
2016年5月-2017年11月苏州儿童医院NICU共收治早产VLBWI255例,符合纳入标准182例,随机分为两组,其中对照组120例,男60例,女60例,胎龄在25周
+6-36周
+1,平均(31.01±1.75)周;出生体重在1.0kg-1.48kg之间,平均(1.29±0.25)kg;小于胎龄儿19例,产时窒息30例,NRDS 34例,宫内感染性肺炎77例,早发型败血症8例。研究组62例,男28例,女34例,胎龄在26周
+6-35周
+4 ,平均(31.05±1.79)周;出生体重在1.0kg-1.44kg之间,平均(1.28±0.23)kg;小于胎龄儿11例,产时窒息14例,NRDS 19例,宫内感染性肺炎39例,早发型败血症3例。两组在性别、胎龄、出生体重、小于胎龄儿、产时窒息、NRDS、宫内感染性肺炎、早发型败血症比较无显著差异(P>0.05),详见表1。
表1两组一般资料比较
2.两组产前孕母一般情况比较
两组产前孕母情况比较发现:孕母年龄≥35岁、剖宫产、产前是否使用激素、胎膜早破、前置胎盘、胎盘早剥、羊水污染、妊娠期糖尿病、妊娠期高血压、产前胆汁淤积在两组间的差异均无统计学意义(P>0.05),见表2。
表2两组产前孕母一般情况比较(n,%)
3.两组间营养情况比较
3.1两组间PN和EN的营养素、热卡摄入比较
生后第7天、第14天,两组PN、EN营养素、热卡摄入量差异不显著(P>0.05);生后第21天,研究组PN营养素及热卡摄入低于对照组,EN营养素及热卡摄入高于对照组,差异均有显著性(P<0.05)。详见表3、表4、表5,图2、图3、图4。
表3两组生后第7天PN和EN营养素、热卡摄入比较
注:t
1、P
1为两组PN对比结果,t
2、P
2为两组EN对比结果。
表4两组生后第14天PN和EN营养素、热卡摄入比较
注:t
1、P
1为两组PN对比结果,t
2、P
2为两组EN对比结果。
表5两组生后第21天PN和EN营养素、热卡摄入比较
注:t
1、P
1为两组PN对比结果,t
2、P
2为两组EN对比结果。
PN(parenteral nutrition)是肠外营养,即静脉营养,EN(enteral nutrition)是肠内营养,即经胃肠道喂养早产儿奶,早产儿生后早期仅予静脉营养,病情平稳后予早产儿奶喂养,即两组均同时存在PN和EN,两组在静脉营养(PN)方面存在不同,对照组注射本院协定配方静脉营养液,容易造成某些营养素相对不足,研究组注射本发明特配液,营养素全面,配比更精细。
3.2两组间体重增长、静脉营养时间比较
两组早产儿的生理性体重下降幅度对比差异不显著(P>0.05),研究组恢复出生体重时间、达半量及全量肠内营养时间均短于对照组,体重增长速率高于对照组,差异显著(P<0.05)。详见表6,图5。
表6两组间体重增长、静脉营养时间比较
极低出生体重儿,基本均为早产儿,各项器官功能发育不全,适应能力较差,存活率低,生后需要关注的问题包括保暖、NRDS、呼吸循环支持、静脉营养、感染、颅内出血、黄疸、电解质紊乱等。静脉营养是早产儿尤其是极低/超低出 生体重儿在NICU治疗期间的一项重要内容。早产VLBWI体重极低,且增长缓慢,死亡率高,新生儿的死亡率约为1.2%,早产儿的死亡率在12.7%-20.8%之间,而VLBWI的死亡率更高;给予早产儿,尤其是VLBWI早期足量的营养支持与呼吸循环支持很重要,甚至提出“营养急救”的概念,认为机体营养状况直接影响药物和器械原有作用的发挥,决定着机体存活与否及存活后的生存质量。因此,国内外均提倡早期“积极”的营养支持以促进生后早期的追赶生长和降低EUGR的发生。早产VLBWI营养指南均提示需要给予较高营养素及热卡,但临床实践中往往受很多因素影响而所供未能达其所需。2013年广东省珠江三角洲地区早产VLBWI多中心研究中报道,生后1、2、4周日均能量摄入中位数EUGR组分别为55kcal/(kg·d)、73kcal/(kg·d)、92kcal/(kg·d),非EUGR组分别为56kcal/(kg·d)、81kcal/(kg·d)、96kcal/(kg·d),EUGR组和非EUGR组均未达到早产儿推荐标准。Liu MY等研究表明,即使尽力供给VLBWI营养物质,积极营养组VLBWI在生后第1周和第2周平均能量摄入分别为71kcal/(kg·d)和103kcal/(kg·d),亦未能达到VLBWI所需。能量摄入不足主要原因可能是早产VLBWI生后一周内生命体征不稳定,部分患儿肠道喂养未建立或仅微量喂养,主要依赖静脉营养,且严重合并症较多,静脉营养受限制所致。
2005年ESPGHAN和ESPEN发布的《儿童肠外营养指南》中提出早产儿相同胎龄胎儿的生长发育速率至少15g/kg·d。本发明中对照组早产儿体重降至最低点后体重增长速率为(15.01±2.05)g/kg·d,研究组体重降至最低点后体重增长速率为(18.25±2.03)g/kg·d,研究组体重增长速率明显高于对照组,说明本发明更有助于促进生长发育。相较对照组,研究组早期添加了脂溶性维生素和水溶性维生素,体重增长更加理想,恢复出生体重时间更短,有助于肠道喂养的建立,水溶性维生素作为体内数十种辅酶的成分,在三大营养素代谢中分工而又协作,配合其他营养素使用,提高营养供应综合效果,最终提高新生儿生长发育。总之,本发明“特配液”中营养素更丰富合理,可以满足VLBWI在生长过程中对能量和营养的需求,保证体重的增长速率,促进肠内营养的建立,尽快达到全量肠内营养,同时降低EUGR发生率。
4.两组间生化指标比较
4.1两组间肝功能指标比较
生后第1天,两组间ALT、γ-GT、总胆红素、直接胆红素水平无显著差异(P>0.05);而生后第7、14和21天,研究组ALT、γ-GT、总胆红素、直接胆红素水平均显著低于对照组(P<0.05);出院前,研究组γ-GT、总胆红素、直接胆红素水平均显著低于对照组(P<0.05)。详见表7,图6。
表7两组肝功能相关指标比较
注:t
1、P
1为两组生后第1天对比结果,t
2、P
2为生后第7天对比结果,t
3、P
3为生后第14天对比结果,t
4、P
4为生后第21天对比结果,t
5、P
5为出院前对比结果。
4.2两组间蛋白质相关指标比较
生后第1天,两组早产儿白蛋白、前白蛋白、球蛋白水平无显著差异(P>0.05);生后第7天,研究组前白蛋白明显高于对照组,对比差异显著(P<0.05),两组白蛋白、球蛋白对比无显著差异(P>0.05);第14、21天及出院前,研究 组白蛋白、前白蛋白、球蛋白水平均高于对照组,对比差异显著(P<0.05)。详见表8,图7。
表8两组蛋白质相关指标比较
注:t
1、P
1为两组生后第1天对比结果,t
2、P
2为生后第7天对比结果,t
3、P
3为生后第14天对比结果,t
4、P
4为生后第21天对比结果,t
5、P
5为出院前对比结果。
4.3两组间电解质指标比较
生后第1天,两组血Na
+、K
+、Ca
2+三项电解质指标水平相当(P>0.05)。生后第7天、第14天、第21天及出院前,两组Na
+水平差异不显著(P>0.05),研究组Ca
2+显著高于对照组,差异显著(P<0.05)。两组K
+于生后第7天、第14天差异显著,研究组高于对照组(P<0.05)。详见表9,图8。
表9两组电解质指标比较(mmol/L)
注:t
1、P
1为两组生后第1天对比结果,t
2、P
2为生后第7天对比结果,t
3、P
3为生后第14天对比结果,t
4、P
4为生后第21天对比结果,t
5、P
5为出院前对比结果。
研究表明,脂肪乳类型可影响肝脏功能,新生儿特别是早产儿,肝细胞膜转运器发育尚不成熟,肝酶系统发育不完全,对胆盐的摄取和处理能力较弱,而LCT主要成分为大豆油,富含ω-6脂肪酸,易在肝脏蓄积,引起肝细胞炎性改变和胆汁分泌减少,导致肝功能损害及胆汁淤积。本发明在静脉营养后ALT、γ-GT、直接胆红素明显低于对照组,说明本发明特配液相较现有临床营养液降低肝功能损害、胆汁淤积;MCT对血浆游离胆红素的影响较小,与血浆白蛋白的亲和力较低,加之其氧化代谢快,能较快从血流中清除,研究组经静脉营养后总胆红素明显低于对照组,黄疸程度相对较轻,说明高胆红素血症患儿使用本发明特配液相对更安全。
临床研究已经证实胎儿期蛋白质水平较低,至妊娠后期,蛋白质水平开始上升 ,故早产儿机体的蛋白质水平往往较低,且出生后各种生理活动会消耗大量蛋白质,随着时间延长消耗蛋白质的速度、总量也随之增加。本发明两组早产儿在早期静脉营养时氨基酸用量无显著差异,但研究组经静脉营养后,白蛋白、前白蛋白、球蛋白水平均高于对照组,其中前白蛋白于生后7天即出现差异,其半衰期短,变化更为敏感,说明“特配液”各种营养素的配比更精细,协同作用更强,更利于氨基酸的利用,其富含脂溶性维生素和水溶性维生素,是氨基酸代谢过程中的重要辅酶,能有效促进蛋白质的合成代谢,使新生儿体内能有一定的蛋白质储备。
出生后72h是早产VLBWI电解质紊乱的高发阶段。在临床治疗过程中,Na
+需要量主要根据血浆测定水平,本发明两组早产儿均未出现明显钠失衡表现。早产儿断脐后,葡萄糖的转运和能量代谢受到限制,细胞能量供应不足,Na
+-K
+-ATP酶活性减弱,细胞中的K
+向外转移,加之生后红细胞不断破坏释放K
+,而肾小球滤过率低,K
+排出量减少,使血清中K
+水平升高,本发明两组早产儿于生后第7、14天血K
+均出现不同程度增高,即非少尿性高钾血症,研究组“特配液”血K
+水平亦明显高于对照组。早产VLBWI早期多合并低钙血症,本发明两组早产儿于生后第7天均出现血Ca
2+水平下降,然后逐渐上升,但研究组血Ca
2+水平始终明显高于对照组,说明本发明特配液维生素组成合理,直接影响血Ca
2+水平。
5.两组间免疫指标比较
5.1两组间体液免疫指标比较
在补体免疫系统中,C3、C4是机体最主要的补体,C3的组分和裂解片断是补体系统发挥作用的核心,C4是补体激活过程中主要的参与成分,在激活经典途径中发挥重要作用。免疫球蛋白中IgG是机体抗感染的主要抗体,但其自身合成缓慢,合成量极少,IgM是初次体液免疫应答早期阶段出现的免疫球蛋白,其作用强于IgG,是最早合成和分泌的抗体。
生后一周内,两组C3、C4、IgM、IgG水平相当,差异无统计学意义(P>0.05)。生后两周末,两组患儿较生后一周内出现C3、IgG降低,C4、IgM上升。组内比较,除C4外,两组其他各项指标前后对比均有统计学意义(P<0.05);两 组间比较,研究组C3、IgG水平明显高于对照组,差异有统计学意义(P<0.05),两组C4、IgM差异不具有统计学意义(P>0.05)。详见表10,图9。
表10两组体液免疫指标对比(g/L)
注:t
1、P
1为对照组前后对比结果,t
2、P
2为研究组前后对比结果,t
3、P
3为两组间生后一周内对比结果,t
4、P
4为两组间生后两周末对比结果。
5.2两组间细胞免疫指标比较
T淋巴细胞中CD3
+为特征性标志指标,即T淋巴细胞总和,可以分为CD4
+、CD8
+细胞两个亚群,CD4
+为免疫调节细胞,CD8
+为免疫抑制细胞。
生后一周内,两组早产儿的CD3
+、CD4
+、CD8
+、CD4
+/CD8
+水平相当,差异无统计学意义(P>0.05)。生后两周末,两组患儿较生后一周内均出现CD3
+、CD4
+、CD4
+/CD8
+上升、CD8
+下降,组内比较,两组各项指标前后对比均有统计学意义,除CD8
+外,其它指标较之前均明显升高(P<0.05);两组间比较,研究组CD3
+、CD4
+、CD4
+/CD8
+水平明显高于对照组(P<0.05),CD8
+水平差异无统计学意义(P>0.05)。详见表11,图10。
表11两组细胞免疫指标比较(%)
注:t
1、P
1为对照组前后对比结果,t
2、P
2为研究组前后对比结果,t
3、P
3为两组间生后一周内对比结果,t
4、P
4为两组间生后两周末对比结果。
早产VLBWI由于过早的离开母体,免疫系统及功能尚未发育成熟,免疫力较差,优化免疫功能,提升自身免疫力,对于改善早产VLBWI的生长发育状况具有重要价值。机体免疫系统主要取决于B淋巴细胞、补体、T淋巴细胞亚群,其发生效果越好,新生儿的免疫功能越好。近年来脂肪乳对于免疫功能的影响备受关注,以往观点认为脂肪乳会对新生儿的免疫功能造成影响,本发明特配液中,脂肪乳剂能够有效降低对机体免疫功能的损害,由于亚油酸和花生四烯酸水平较低,前列腺素E2生成减少,其亚油酸和花生四烯酸含量较低,能够减少前列腺素E2的形成量,进而减轻免疫抑制,进入人体后,血液中的脂肪乳清除速度快,网状内皮系统负荷低,对免疫功能影响小,另有本发明注重维生素的配合,可提高早产儿的免疫力;因此对新生儿免疫功能的影响很小。本实施例结果显示,经静脉营养后研究组C3、IgG相较对照组下降幅度更小,CD3
+、CD4
+、CD4
+/CD8
+上升幅度更大,对比差异显著,表明使用20%的MCT/LCT、富含维生素的“特配液”对体液免疫功能的影响更小,且能在一定程度上改善VLBWI的细胞免疫功能。
6.两组并发症发生情况比较
研究组PNAC、NEC、BPD、低血糖、ROP、晚发型败血症、BIPI发生率明显 低于对照组,差异有统计学意义(P<0.05)。详见表12,图11。
表12两组并发症发生率比较(n,%)
本研究发现,研究组PNAC发生率低于对照组,说明现有营养液更易引起胆汁淤积。本发明研究组NEC、晚发型败血症发生率低于对照组,说明丰富的营养素有助于降低院内感染的发生,注重补充微量营养素对提高免疫力、防治并发感染有重要作用。本研究发现研究组达半量、全量肠内喂养时间均较对照组早,BPD、低血糖发生率较对照组低,说明BPD、低血糖发生与肠内营养相关联,早期给予肠内及肠外营养可有效减少BPD发生,早期肠道喂养可改善患儿胃肠功能,减少喂养不耐受,更快达到全肠内营养,缩短住院时间,还可降低低血糖的发生。目前早产儿、低出生体重是一致公认的ROP发病的根本原因,生后体质量增长缓慢也是增加极低出生体质量婴儿ROP的患病风险,营养摄入不足易患1区ROP,生长速率缓慢可以发生包括1区ROP在内的任何ROP,本发明研究组患儿体重增长速率较对照组快,ROP发生率较对照组低,说明丰富合理的营养素配比能在一定程度上减少ROP的发生。
早产VLBWI早期营养状况不仅影响近期的生长发育,对神经系统发育也有不可逆的长期影响,本发明研究组生化指标中蛋白质储备较对照组高,BIPI发生率较对照组低,说明“特配液”中氨基酸的利用度更高,有助于促进早产儿早期神经系统发育,降低BIPI的发生风险;积极的蛋白质支持,可显著改善早产儿远期的生长和神经发育预后,可以提高氮的利用,有效促进早产儿的神经发育,减少颅内出血、脑白质软化等早产儿脑损伤的发生。
7.两组临床治疗结局比较
对照组120例患儿中,治愈95例,好转24例,治愈率79.17%,好转率20%,无死亡病例,转院1例(因4期ROP转上海行手术治疗);研究组62例,治愈49例,好转13例,治愈率79.03%,好转率20.96%,无死亡及转院病例,两组治愈率、好转率无显著差异(P>0.05)。研究组以体重评价EUGR发生率低于对照组,住院时间短于对照组,住院费用略低于对照组,差异有统计学意义(P<0.05)。详见表13,图12。
表13两组临床治疗结局比较
早期积极的静脉营养对疾病的预后有明显改善作用。本研究中两组早产儿出院时疾病治愈率、好转率无明显差异,考虑原因是部分小早产儿早期合并严重基础疾病、并发症家属放弃治疗,而未纳入本研究。研究组体重增长速率明显高于对照组,其EUGR发生率也较低,并发症亦较低,相较对照组能更快达到早产儿出院标准,缩短了患儿的住院时间,略省住院费用。
综上所述,早产VLBWI各系统功能尚未发育成熟,并发症多发,对营养的需求量大,却无法通过喂养来满足,因此静脉营养为早期主要营养方式。“特配液”营养素更精确、全面,配比更合理,利用度高,更符合早产VLBWI对营养物质、能量的需求,有利于促进生长发育,优化生化指标,改善肝功能,补充蛋白质,平衡电解质,提升细胞免疫功能,且安全有效,缩短住院时间,降低EUGR的发生率;尤其是临床结果显示本发明特配液不仅降低死亡率,更主要是优化早产儿生活质量。
结论
关于“极低出生体重儿静脉营养”相关资料繁杂,这一事实使本次研究开展的难度加大,在本发明前在知网、Pubmed、万方、维普、读秀、外文期刊网以及专 利查询网中广泛搜集相关研究资料,但相关性研究较少。本发明“特配液”营养素更丰富全面,生物利用度高,能够有效促进早产VLBWI追赶生长,提高体重增长速率,缩短恢复出生体重时间、达半量及全量肠内营养时间,优化生化指标,改善肝功能,平衡电解质,且基本不会对免疫系统造成不良影响,反而在一定程度上能够提升细胞免疫功能,降低PNAC、NEC、BPD、低血糖、ROP、晚发型败血症、BIPI等并发症发生率,效果理想,临床应用价值高。
Claims (10)
- VLBWI营养管理用特配液,其特征在于,所述VLBWI营养管理用特配液的制备方法包括以下步骤,将脂肪乳剂、氨基酸、葡萄糖、电解质、维生素在无菌条件下混合,得到VLBWI营养管理用特配液;所述脂肪乳剂为中长链脂肪乳剂。
- 根据权利要求1所述VLBWI营养管理用特配液,其特征在于,所述维生素由水溶性维生素以及脂溶性维生素组成;所述电解质为氯化钠,或者氯化钠和氯化钾。
- 根据权利要求1所述VLBWI营养管理用特配液,其特征在于,脂肪乳剂、氨基酸、葡萄糖、电解质、维生素分别以脂肪乳剂注射液、氨基酸注射液、葡萄糖注射液、电解质注射液、维生素注射液形式存在。
- 根据权利要求3所述VLBWI营养管理用特配液,其特征在于,以100毫升VLBWI营养管理用特配液计,其中脂肪乳剂注射液为5~6mL,氨基酸注射液为40mL,电解质注射液为2mL,维生素注射液为1.8~2.5mL,葡萄糖注射液为余量。
- 根据权利要求4所述VLBWI营养管理用特配液,其特征在于,维生素注射液由体积比为1的水溶性维生素注射液以及脂溶性维生素注射液组成;葡萄糖注射液由体积比为4∶1的10%葡萄糖注射液、50%葡萄糖注射液组成。
- 根据权利要求5所述VLBWI营养管理用特配液,其特征在于,所述VLBWI营养管理用特配液的制备方法如下:将电解质注射液、葡萄糖注射液、氨基酸注射液、水溶性维生素注射液混合得到注射液A;将脂溶性维生素注射液、脂肪乳剂注射液混合得到注射液B;混合注射液A与注射液B,得到VLBWI营养管理用特配液。
- 根据权利要求5所述VLBWI营养管理用特配液,其特征在于,脂肪乳剂注射液为20%中长链脂肪乳剂注射液。
- 根据权利要求5所述VLBWI营养管理用特配液,其特征在于,氨基 酸注射液为6.7%的小儿复方氨基酸水溶液;水溶性维生素注射液为水乐维他复方制剂;脂溶性维生素注射液为维他利匹特复方制剂。
- 权利要求1所述VLBWI营养管理用特配液在制备VLBWI营养管理营养液中的应用。
- 根据权利要求9所述的应用,其特征在于,所述应用遵循2013年《中国新生儿营养支持临床应用指南》。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910804272.X | 2019-08-28 | ||
CN201910804272 | 2019-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021035854A1 true WO2021035854A1 (zh) | 2021-03-04 |
Family
ID=69039275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/107976 WO2021035854A1 (zh) | 2019-08-28 | 2019-09-25 | Vlbwi营养管理用特配液及其制备方法与应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110651999B (zh) |
WO (1) | WO2021035854A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110651999B (zh) * | 2019-08-28 | 2023-02-17 | 苏州大学附属儿童医院 | Vlbwi营养管理用特配液及其制备方法与应用 |
CN111863195A (zh) * | 2020-07-28 | 2020-10-30 | 仝淑花 | 基于医院信息系统的新生儿肠内外营养医嘱管理系统 |
CN114028424A (zh) * | 2021-12-06 | 2022-02-11 | 首都医科大学附属北京世纪坛医院 | 一种低出生体重新生儿标准化静脉营养液配方及配置装置 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101378669A (zh) * | 2006-01-31 | 2009-03-04 | 雀巢技术公司 | 用于低出生体重儿的营养组合物 |
CN101437411A (zh) * | 2006-03-23 | 2009-05-20 | 荷兰纽迪希亚公司 | 早产儿配方 |
WO2013148353A1 (en) * | 2012-03-30 | 2013-10-03 | Baxter Corporation Englewood | Systems and methods for determining ingredient amounts for preparations for administration to patients |
WO2013191533A1 (en) * | 2012-06-18 | 2013-12-27 | N.V. Nutricia | Metabolic imprinting effects of nutrition with large lipid globules comprising milk fat and vegetable fat |
US20140057014A1 (en) * | 2012-08-27 | 2014-02-27 | Carol Lynn Berseth | Formula Fortifier |
CN107705825A (zh) * | 2017-09-25 | 2018-02-16 | 南京市儿童医院 | 一种基于MicrosoftExcel的儿童肠外营养计算表制作方法 |
CN110651999A (zh) * | 2019-08-28 | 2020-01-07 | 苏州大学附属儿童医院 | Vlbwi营养管理用特配液及其制备方法与应用 |
-
2019
- 2019-09-25 CN CN201910913503.0A patent/CN110651999B/zh active Active
- 2019-09-25 WO PCT/CN2019/107976 patent/WO2021035854A1/zh active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101378669A (zh) * | 2006-01-31 | 2009-03-04 | 雀巢技术公司 | 用于低出生体重儿的营养组合物 |
CN101437411A (zh) * | 2006-03-23 | 2009-05-20 | 荷兰纽迪希亚公司 | 早产儿配方 |
WO2013148353A1 (en) * | 2012-03-30 | 2013-10-03 | Baxter Corporation Englewood | Systems and methods for determining ingredient amounts for preparations for administration to patients |
WO2013191533A1 (en) * | 2012-06-18 | 2013-12-27 | N.V. Nutricia | Metabolic imprinting effects of nutrition with large lipid globules comprising milk fat and vegetable fat |
US20140057014A1 (en) * | 2012-08-27 | 2014-02-27 | Carol Lynn Berseth | Formula Fortifier |
CN107705825A (zh) * | 2017-09-25 | 2018-02-16 | 南京市儿童医院 | 一种基于MicrosoftExcel的儿童肠外营养计算表制作方法 |
CN110651999A (zh) * | 2019-08-28 | 2020-01-07 | 苏州大学附属儿童医院 | Vlbwi营养管理用特配液及其制备方法与应用 |
Non-Patent Citations (4)
Title |
---|
CHENG YU , LI JING , FENG YI , BEI FEI: "The relationship between the doses in parenteral nutrition and short term outcomes in very low birth weight infants", JOURNAL OF CLINICAL PEDIATRICS, vol. 34, no. 9, 15 September 2016 (2016-09-15), pages 657 - 660, XP055786124, ISSN: 1000-3606, DOI: 10.3969/j.issn.1000-3606.2016.09.004 * |
FANG HONG-XIA: "The effect of lipid emulsion in early parenteral nutrition on very low birth weight infants", PARENTERAL & ENTERAL NUTRITION, vol. 17, no. 1, 10 January 2010 (2010-01-10), pages 23 - 25, XP055786141, DOI: 10.16151/j.1007-810x.2010.01.014 * |
SU-FANG CHANG , CHONG-MIN XU, LIN WANG: "Study on Lipid Peroxidation of Fat Emulsion and Clinical Safety in Infants with Very Low Birth Weight", JOURNAL OF APPLIED CLINICAL PEDIATRICS, vol. 22, no. 18, 20 September 2007 (2007-09-20), pages 1415 - 1417, XP009526608, ISSN: 2095-428X * |
TIAN YAN: "The Study on the Early Individualized Parenteral Nutrition for Premature Infants", CHINESE MASTER'S THESES FULL-TEXT DATABASE, 1 May 2009 (2009-05-01), pages 1 - 46, XP055786102 * |
Also Published As
Publication number | Publication date |
---|---|
CN110651999B (zh) | 2023-02-17 |
CN110651999A (zh) | 2020-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021035854A1 (zh) | Vlbwi营养管理用特配液及其制备方法与应用 | |
Ariceta et al. | Cystinosis in adult and adolescent patients: recommendations for the comprehensive care of cystinosis | |
Watson et al. | Neonatal effects of maternal treatment with the anticonvulsant drug diphenylhydantoin | |
Kollee et al. | Persistent neonatal hypoglycaemia due to glucagon deficiency. | |
Schanler | The low birth weight infant | |
Hurst et al. | The use of B-adrenergic blocking agents in pregnancy and lactation | |
Ditzenberger et al. | Supplemental protein and postnatal growth of very low birth weight infants: a randomized trial | |
Kumaran et al. | Respiratory distress syndrome in infants-an overview | |
WO2012084459A1 (en) | Prevention and therapy methods for preterm deliveries and births | |
Rahmoune et al. | Alagille syndrome and pregnancy: anesthetic management for cesarean section | |
Brewer et al. | Epilepsy and pregnancy: maternal and fetal effects of phenytoin | |
Aminisani et al. | Zinc supplementation during pregnancy: a randomized controlled trial | |
NICU | MAR Pediatrics (2023) 4: 3 Research Article | |
Robinson et al. | Identifying maternal conditions affecting altered embryologic development | |
Khorsheed | Review of Patients With Abo Incompatibilty In Healthy Neonatal Jaundice In Kirkuk | |
Oteng-Ntim et al. | Sickle cell disease in pregnancy | |
CN115515566A (zh) | 维生素a棕榈酸酯的组合物、其制备工艺、包括其的用途和方法 | |
Ramos et al. | Influence of Vitamin D Supplementation in the Gestational Period in Patient with Multiple Sclerosis: A Case Report | |
Ahmed et al. | Comparison of maternal serum and neonatal cord blood levels of zinc in relation to birth weight and period of gestation | |
Lin et al. | Pregnant Diseases | |
Nematovna | COURSE AND TREATMENT METHODS OF ACUTE INTESTINAL INFECTIONS IN CHILDREN | |
Sravani | Study of Early Inhaled Budesinide Therapy in Meconium Aspiration in Term and Post Term Neonates | |
Xie et al. | Clinical Effects of Cervical Dilation Balloon and Castor Oil Meal Nursing Interventions in Term Induction of Labor | |
Behafarin et al. | Assessment of the clinical outcomes of diabetes exposure during pregnancy on mothers and their neonates. A cohort study | |
Waks et al. | 349 Antenatal aspirin prescription following the United States preventive services task force’s (USPSTF) 2021 practice update |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19943474 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19943474 Country of ref document: EP Kind code of ref document: A1 |